ArticleScientific reports2025
KDM6A deficiency promotes tumor progression and resistance to cabozantinib treatment in clear cell renal cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Lysine (K)-specific demethylase (KDM) 6A, a histone modifier with inhibitory roles in many types of cancers, is frequently mutated in clear cell renal cell carcinoma (ccRCC). Here, we investigated the role of KDM6A in ccRCC progression, including its effect on resistance to tyrosine kinase inhibitors (TKIs). The clinical impact of KDM6A expression was examined by immunohistochemical analysis of nephrectomized tissues from patients with ccRCC. Upon generation of KDM6A-deficient RCC cells by CRISPR/Cas9-mediated gene editing, in vitro cancer cell property analysis, RNA sequencing, and in vivo murine xenograft model examination were performed. The relationship between KDM6A expression and efficacy of TKIs was analyzed using data from public databases and in vitro pharmacological assessments. Patients with KDM6A-low ccRCC had poor prognoses. Promoted invasion, migration, cancer stemness, epithelial-mesenchymal transition (EMT), and in vivo tumor progression were observed in KDM6A-deficient RCC cells. A reanalysis of previous clinical trial data revealed lower efficacy of sunitinib in patients with KDM6A-low ccRCC. Consistently, KDM6A-deficient cells showed resistance to cabozantinib and decreased expression of target molecules of TKIs. KDM6A deficiency contributes to ccRCC progression and TKI resistance, suggesting that targeting KDM6A-related pathways may offer new therapeutic strategies for patients with KDM6A-deficient ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.